Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland.

ABSTRACT:

Background

Comorbidities are common among people with multiple sclerosis (pwMS) and have been suggested to affect the usage of disease-modifying treatments (DMTs).

Objectives

We investigated the prevalence and types of comorbidities in newly diagnosed pwMS, as well as the associations between comorbidities and the choice and persistence of the initial DMT.

Methods

This retrospective register study used data from the Finnish MS register (85% of national coverage). The inclusion criteria were a diagnosis of relapsing-remitting MS between 2010 and 2022, the first DMT started between 2016 and 2022, and an age of at least 18 years. The exclusion criteria were a diagnosis of secondary progressive MS and initiation of azathioprine or mitoxantrone.

Results

The inclusio

SUBMITTER: Ahvenjarvi H 

PROVIDER: S-EPMC12804660 | biostudies-literature | 2026 Jan-Mar

REPOSITORIES: biostudies-literature